Neurocrine Biosciences (NASDAQ:NBIX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:30 AM.
Here's what investors need to know about the announcement.
Earnings
Neurocrine Biosciences missed estimated earnings by 11.76%, reporting an EPS of $0.3 versus an estimate of $0.34.
Revenue was up $74.00 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.48 which was followed by a 7.45% increase in the share price the next day.
Here's a look at Neurocrine Biosciences's past performance:
| Quarter | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|
| EPS Estimate | 0.52 | 0.60 | 0.49 | 0.51 |
| EPS Actual | 0.04 | 0.64 | 0.63 | 0.49 |
| Revenue Estimate | 316.79M | 297.65M | 274.38M | 250.63M |
| Revenue Actual | 312.00M | 296.00M | 288.90M | 236.60M |
To track all earnings releases for Neurocrine Biosciences visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
